BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path

Reuters

10 Jan

BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path

Jan 10 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O:

4DMT ANNOUNCES POSITIVE INTERIM DATA FROM 4D-150 SPECTRA CLINICAL TRIAL IN DME AND ALIGNMENT WITH FDA ON REGISTRATIONAL PATH
4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO INTRAOCULAR INFLAMMATION OBSERVED

Source text: nGNX9y1cRq

Further company coverage: FDMT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502865814"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502865814\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2502865814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502865814","market":"us","top_or_hot":-1,"title":"BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path</title></head><body><p><span>Jan 10 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> Inc <span>FDMT.O</span>:</p><ul><li><p>4DMT ANNOUNCES POSITIVE INTERIM DATA FROM 4D-150 SPECTRA CLINICAL TRIAL IN DME AND ALIGNMENT WITH FDA ON REGISTRATIONAL PATH</p></li><li><p>4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO INTRAOCULAR INFLAMMATION OBSERVED</p></li></ul><p>Source text: <span>nGNX9y1cRq</span></p><p>Further company coverage: <span>FDMT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-10 21:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path</title></head><body><p><span>Jan 10 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> Inc <span>FDMT.O</span>:</p><ul><li><p>4DMT ANNOUNCES POSITIVE INTERIM DATA FROM 4D-150 SPECTRA CLINICAL TRIAL IN DME AND ALIGNMENT WITH FDA ON REGISTRATIONAL PATH</p></li><li><p>4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO INTRAOCULAR INFLAMMATION OBSERVED</p></li></ul><p>Source text: <span>nGNX9y1cRq</span></p><p>Further company coverage: <span>FDMT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA26TXGX:1","article_id":"2502865814","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502865814","pubTimestamp":1736515161,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational PathJan 10  - 4D Molecular Therapeutics Inc FDMT.O:4DMT ANNOUNCES POSITIVE INTERIM DATA FROM 4D-150 SPECTRA CLINICAL TRIAL IN DME AND ALIGNMENT WITH FDA ON REGISTRATIONAL PATH4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO INTRAOCULAR INFLAMMATION OBSERVEDSource text: nGNX9y1cRqFurther company coverage: FDMT.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BRIEF-4DMT报告DME 4D-150 SPECTRA临床试验的积极中期数据，并在注册路径上与FDA保持一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FDMT":0.9},"content_text":"BRIEF-4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational PathJan 10 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O:4DMT ANNOUNCES POSITIVE INTERIM DATA FROM 4D-150 SPECTRA CLINICAL TRIAL IN DME AND ALIGNMENT WITH FDA ON REGISTRATIONAL PATH4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO INTRAOCULAR INFLAMMATION OBSERVEDSource text: nGNX9y1cRqFurther company coverage: FDMT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}